Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday.
David Risinger has given his Buy rating due to a combination of factors, primarily focusing on the potential of Sanofi’s pipeline, particularly amlitelimab. Despite the initial setback in the Ph2 TIDE-Asthma trial where amlitelimab did not meet its primary endpoint at week 48, the drug demonstrated promising results by week 60, showing significant reductions in exacerbation rates and improvements in lung function and asthma control.
Furthermore, Sanofi’s strategic decision to advance amlitelimab into Phase 3 development underscores its confidence in the drug’s potential, especially given its performance in a biomarker-defined subgroup. The company has identified amlitelimab as one of its top three pipeline assets, with a peak sales potential exceeding €5 billion, highlighting its significance in Sanofi’s growth strategy. Additionally, ongoing trials in other conditions such as atopic dermatitis, alopecia areata, celiac disease, and scleroderma further bolster the long-term prospects of Sanofi’s pipeline, justifying the Buy rating.
Risinger covers the Healthcare sector, focusing on stocks such as Sanofi, Eli Lilly & Co, and Vertex Pharmaceuticals. According to TipRanks, Risinger has an average return of 6.3% and a 48.18% success rate on recommended stocks.
In another report released yesterday, Exane BNP Paribas also initiated coverage with a Buy rating on the stock with a €115.00 price target.